We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Spark Therapeutics has earned a $15 million milestone payment from Pfizer for achieving a pre-specified safety and efficacy profile in the ongoing hemophilia B Phase 1/2 trial of SPK-9001.